METHOD OF PRODUCING RECOMBINANT DIMERIC ENZYME

Abstract: This invention relates to a method of producing a recombinant eukaryotic heterodimeric enzyme using a prokaryotic host. The method involves constructing a first DNA vector containing DNA encoding one of the subunits of the dimeric enzyme and then constructing a second DNA vector containing DNA encoding the second subunit of the enzyme. Once the DNA vectors are constructed, they are used to transform a prokaryotic host. The transformed prokaryotic host cell is then cultured under conditions appropriate for the expression of the dimeric enzyme. For example, using the method of the present invention, the heterodimeric isoform of creating kinase CKMB can be produced. This invention further relates to a method of producing a recombinant human dimeric enzyme in an active form using a prokaryotic host, the recombinant enzyme products produced using the method of the present invention, and a transformed prokaryotic host constructed by the method of the present invention.

Description: METHOD OF PRODUCING RECOMBINANT DIMERIC ENZYME Background of the Invention The analysis of creatine inase (CK) isoforms is important for the early diagnosis of acute myocardial infarction (AMI) and for the early determination of coronary artery reperfusion in patients treated with thrombolytic therapy (Alan and Wu, Laboratory Medicine. 23(5) :297-302. 1992) . The CK isoforms CKMM and CKMB can be used to determine the success of reperfusion therapy, although measurement of MB isoforms provides the earliest and most definitive results. Levels of MM isoforms are also elevated in patients with skeletal muscle disease, and together with the relative MB index, can be useful for determining whether the muscle damage is acute or chronic. Pure CKMB is needed for research studies of myocardial metabolism and the enzyme's catalytic mechanism and for preparation of standards and quality control materials for clinical analysis. Current methods of obtaining CKMB involve homogenizing heart tissue and precipitating the CKMB with ethanol or ammonium sulfate followed by ion exchange, gel filtration, and/or affinity chromatography (Grace and Roberts, Clin Che Acta, 123 : 59- 71, 1982; and Herman and Roberts, Anal Biochem, 1^6:244-252, 1980) . These procedures involve multiple column- purification steps, are long and tedious, and may result in poor yields and low specific activities. In addition, the extracts of CKMB can contain large amounts of contaminants, such as albumin which co-fractionates and co-migrates with CKMB on chromatography and pathogens requiring special handling. A need exists to improve and simplify the production of the different isoforms of CK to satisfy the requirements of researchers and clinicians. Snτt-ιιwaτ"y of the Invention This invention relates to a method of producing a recombinant eukaryotic heterodimeric enzyme in an active form using a prokaryotic host. The method involves constructing a first DNA vector containing DNA encoding one of the subunits of the heterodimeric enzyme and, then constructing a second DNA vector containing DNA encoding the second subunit of the enzyme. Once the DNA vectors are constructed they are used to transform a prokaryotic host. The transformed prokaryotic host cell is then cultured under conditions appropriate for the expression of the heterodimeric enzyme. For example, using the method' of the present invention, the heterodimeric iosform of creatine kinase, i.e., CKMB, can be produced. This invention further relates a method of producing a recombinant human dimeric enzyme in an active form using a prokaryotic host. Furthermore, the present invention relates to the recombinant enzyme products produced using the method of the present invention. The invention further relates to a transformed prokaryotic host constructed by the method of the present invention. Brief Description of the Drawing Figure 1 a schematic illustration of the method of producing a recombinant dimeric enzyme of the present invention. Detailed Description of the Invention This invention is based upon the discovery that different isoforms of creatine kinase (i.e., CKBB, CKMM and CKMB) can be produced by constructing a DNA vector for the two different subunits of the enzyme and transforming a host cell with the two DNA vectors, the resulting transformed host cell being capable of expressing CKBB, CKMM and CKMB. DNA vector The term "DNA vector" is intended any replication competent vector which has the capability of having a DNA fragment inserted into it and, subsequently, the expression of that DNA insert by an appropriate host cell. In addition, the DNA vector must be receptive to the insertion of a DNA fragment containing the DNA where the sequence encodes the subunits of the target eukaryotic dimeric enzyme such as creatine kinase (i.e., CKM and CKB) . Furthermore, the DNA vector must contain a promoter which can be recognized by the host cell. Procedures for the construction of DNA vectors include those described in Maniatis et al . , Molecular Cloninσ. A Laboratory Manual. 2d, Cold Spring Harbor Laboratory Press (1989), herein referred to as Maniatis et al . . The term "DNA fragment" is intended to encompass any DNA fragment that encodes an enzyme sύbunit. The DNA fragment once inserted into a DNA vector should be transmittable to a host microorganism by transformation or conjugation or transfection. Procedures for the construction or extraction of DNA fragments include those described in Maniatis et al . and others known by those skilled in the art. Host The transformed prokaryotic host of the present invention can be created by various methods by those skilled in the art. For example, transfection, transformation or electroporation as explained by Maniatis et al . can be used. By the term "prokaryotic host" is intended any prokaryote capable of the uptake and expression of foreign DNA, i.e., DNA not originally a part of the prokaryotes ' s nuclear material. Suitable prokaryotes may include CoryneJacterium, Escherichia, Streptomyces or Bacillus. Recombinant Dimeric Enzyme The recombinant dimeric enzyme of the present invention is intended to encompass any protein consisting of two subunits and possessing enzymatic properties. The invention will be further illustrated by the following non-limiting Exemplification: - A - EXEMPLIFICATION Materials and Methods: Cloninσ CKMB cDNA using PCR DNA fragments carrying cDNA encoding CKM and CKB proteins that had been cloned from a human cDNA library have been described (Perryman et al . , Biochem. and Biophvs. Reasearch Comm.. 140: 981-989, 1986; and Villarreal-Levy et al . , Biochem. and Biophvs. Reasearch Comm., 144:1116-1127, 1987) . We used PCR amplification to change the DNA sequence at the N- and C- termini to add restriction enzyme sites that were suitable for cloning the CK cDNA into Genzyme expression vectors. PCR primers were synthesized at Genzyme. The primers had the following 5' - 3' sequences; SL22 (Ndel site at the ATG start codon of CKB) GCC CAT ATG CCC TTC TCC AAC AGC CAC A SL23 (EcoRl site after the stop codon of CKB) GGA ATT CAT TTC TGG GCA GGC ATG AGG SL24 (Ndel site at the ATG start codon of CKM) GCC CAT ATG CCA TTC GGT AAC ACC CAC AAC SL25 (BamHl site after the stop codon of CKM) GCA GGA TCC TAC TTC TGG GCG GGG ATC AT. The GeneAmp PCR Reagent Kit with AmpliTaq DNA Polymerase from Perkin Elmer Cetus (Norwalk, CT) was used for PCR reactions. The reactions were carried out following standard procedures outlined in the literature enclosed in the kit. Specifically, 5-30 ng DNA, 100 pmol primer DNA, 2.5 U AmpliTaq DNA polymerase, and 200 μmol dATP, dCTP, dGTP, dTTP were mixed with supplied buffer, and the reaction mix was overlayed with Ampliwax (Perkin Elmer Cetus) . The PCR machine (Coy Laboratory Products, Inc. Grass Lake, MI) was programmed for a cycle of 94'C (melt) for 2 minutes, 55'C (anneal) for 2 minutes, 72'C (extend) for 2 minutes, this cycle was repeated 18 times. A final extension step was run for 10 minutes to allow for complete polymerization of all strands. PCR product (approximately 5-10 μg) was digested with Ndel and EcoRl (for CKB) or Ndel and BamHl (for CKM) and purified by electrophoresis through a 0.7% low melting point agarose TAE buffered gel (FMC BioProducts, Inc. Rockland, ME) for cloning into expression vectors. Electrophoresis was performed as described in Molecular Cloning (Sambrook, Fritsch and Maniatis, 1989. Cold Spring Harbor Press, Cold Spring Harbor, NY) . Restriction endonucleases were purchased from New England BioLabs (Beverly, MA) and digestion reactions set up as suggested by the manufacturer . DNA fragments were purif ied from gel slices using the Geneclean kit (BiolOl , La Jolla , CA) . Constructing the Genzyme Expression Vector pRZ38 The expression vector was constructed at Genzyme as a derivative of the plasmid pBluescript SK +/ - ( available from Stratagene , La Jolla , CA) . Expression is driven of f the Lac promoter . Our vector , pRZ38 , was constructed by adding an restriction enzyme site at the ATG s tart codon of the b-galactos idase gene through s ite-directed mutagenesis . Mutagenes is protocols were followed as described using the Muta-Gene In Vitro Mutagenesis Kit from BioRad (Richmond, CA) . This change in the vector allows cloning of foreign genes after the LacZ promoter but maintains similar spacing from the promoter as in the native gene . Cloning CKM and CKB DNA into PRZ38 Vector DNA ( 5 μg) was digested with Ndel and EcoRl ( for CKB) or Ndel and BamHl ( for CKM) and gel purified as above . Approximately 100 ng digested vector DNA and 100 ng digested PCR product were ligated in a 20 μl reaction (T4 DNA ligase purchased from NEB , Beverly , MA) . Ligation reactions set up as described in Molecular Cloning . After overnight incubation at 15 ' C ligation mixes were diluted to 60μl with dH20. lμl of each was electroporated into electroporation competent E . coli strain MC1061 . The Cell-Porator and Voltage Booster were purchased from Bethesda Research Labs (Bethesda , MD) . Protocols for competent cell preparation and electroporation are described in the Instruction manual . Transf ormants were selected on LB agar plates supplemented with 50 μg/ml ampicillin . Transf ormants were analyzed for harboring the correct recombinant plasmid using the alkaline lysis miniprep technique (Molecular Cloning) . Miniprep DNA was analyzed by restriction enzyme mapping . 25 ml cultures of pRZ52 (CKB) and pRZ53 (CKM) were grown in LB with 50μg/ml ampicillin and larger scale DNA preps were purified using QIAGEN plasmid purif ication columns ( QIAGEN Corp . , Chatsworth , CA) . Dideoxynucleoside chain-termination DNA sequencing reactions were carried out according to the standard protocols described in the Sequenase 2.0 kit from USB (Cleveland, OH) . [-35S]-dATP (New England Nuclear) was used to radiolabel the sequences for visualization on Kodak XAR film. Reactions were separated through a 6% polyacrylamide gel, the gel dried, and exposed to film as described in Molecular Cloning. The DNA sequence representing the coding regions of CKB and CKM are in figure Gl and 2. Once the CKM DNA sequence was determined to be correct the ampicillin resistance gene in pRZ53 was exchanged for the kanamycin resistance gene from Tn903 (Nomura et al . , Gene. 3:39-51, 1987) . The ampicillin gene was cut out using the restriction enzymes Sspl and Bp l, and the vector ends were blunt ended using T4 polymerase. The kanamycin resistance gene had been cloned into the polylinker in a pBR322 vector. The gene was cut out of the vector using BamHl and was blunt ended with T4 polymerase. The resulting CKM plasmid is referred to as pRZ69. Constructing the CKMB Co-expression Strain pRZ52 and pRZ69 DNA was mixed together in a concentration of approximately 50 μg/ml and 1 μl of the mixture electroporated into 20 μl MC1061 cells. The cells were plated onto LB plates containing 50 μg/ml ampicillin and 50 μg/ml kanamycin to select for cells that had been co-transformed with both plasmids . Co-transformants were analyzed by restriction digestion of miniprep DNA (the standard technique is described in Molecular Cloning) . Analyzing Expression Expression analysis of the co-transformants was carried out as follows. Clones were grown overnight in 2 ml LB, 0.2% glucose, 50 μg/ml kanamycin and 50 μg/ml ampicillin at 37'C shaking. In the morning 25 ml of LB with 50 μg/ml kanamycin and 50 μg/ml ampicillin was inoculated with 0.6 ml of the overnight culture and grown at 30'C shaking. Cultures were grown to A600 about 0.4 then sampled at one hour intervals for 4 hours . Cultures were left growing overnight and an additional sample taken. Whole cell samples were boiled in SDS-PAGE sample buffer and run through 12% polyacrylamide gels to assess protein production. Gels were obtained from BioRad, and protocols provided with gels were followed. Several assays were used to determine the level and quality of the expressed recombinant protein. Cultures were grown as previously described. At A600 approximately 1.0 or after overnight incubation cells were harvested and resuspended in a lysis buffer (20 mM Bis-Tris pH 6.9, 0.25% Tween 20, 10 mM b-mercaptoethanol, 10 mM EDTA, 10 mM EGTA, ImM PMSF) . The resuspended cells were lysed by sonication on ice (or for larger scale analysis cells were lysed using the Microfluidizer from Microfluidics Corp., Newton, MA ) and the cell debris removed by centrifugation. Samples were analyzed using the following assay systems after diluting into lysis buffer. The Creatine Kinase Reagent (Sigma 47-UV) is a spectrophotometric assay for kinetic determination of enzyme activity. The Creatine Phosphokinase (CPK) Isoenzymes Kit (Sigma 715-EP) separates the various isoforms (MM, MB, and BB) and stains for activity. The CK-MB assay system for the Abbott IMx analyzer uses a microparticle enzyme immunoassay (MEIA) to determine specific protein mass of CK-MB in a sample. (All protocols are provided with the assay kits. ) Equivalents Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims: SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: Ziegler, Robin J. Long, Sue (ii) TITLE OF INVENTION: Method of Producing Recombinant Dimeric Enzyme (iii) NUMBER OF SEQUENCES: 4 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Bill Gosz, Esq., Genzyme Corporation (B) STREET: One Kendall Square (C) CITY: Cambridge (D) STATE: MA (E) COUNTRY: U.S.A. (F) ZIP: 02139 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentln Release #1.0, Version #1.25 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: US (B) FILING DATE: (C) CLASSIFICATION: (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: William G Gosz (B) REGISTRATION NUMBER: 27,787 (C) REFERENCE/DOCKET NUMBER: GEN3-10.0 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (617) 252-7583 (B) TELEFAX: (617) 252-7600 (C) TELEX: 201223 GENCAMB (2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1146 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear ( ii ) MOLECULE TYPE : cDNA ( iii ) HYPOTHETICAL : NO ( iv) ANTI- SENSE : YES (v) FRAGMENT TYPE : N-terminal (vi ) ORIGINAL SOURCE : (A) ORGANISM: Homo sapiens (xi ) SEQUENCE DESCRIPTION: SEQ ID NO : l : ATGCCCTTCT CCAACAGCCA CAACGCACTG AAGCTGCGCT TCCCGGCCGA GGACGAGTTC 60 CCCGACCTGA GCGCCCACAA CAACCACATG GCCAAGGTGC TGACCCCCGA GCTGTACGCG 120 GACGTGCGCG CCAAGAGCAC GCCGAGCGGC TTCACGCTGG ACGACGTCAT CCAGACAGGC 180 GTGGACAACC CGGGCCACCC GTACATCATG ACCGTGGGCT GCGTGGCGGG CGACGAGGAG 240 TCCTACGAAG TGTTCAAGGA TCTCTTCGAC CCCATCATCG AGGACCGGCA CCGGCGCTAC 300 AAGCCCAGCG ATGACGACAA GACCGACCTC AACCCCGACA ACCTGCAGGG CGGCGACGAC 360 CTGGACCCCA ACTACGTGCT GAGCTCGCGG GTGGCCACGG GCCGCAGCAT CCGTGGCTTC 420 TGCCTCCCCC CGCACTGCAG CCGCGGGGAG CGCCGAGCCA TCGAGAAGCT CGCGGTGGAA 480 GCCCTGTCCA GCCTGGACGG CGACCTGGCG GGCCGATACT ACGCGCTCAA GAGCATGACG 540 GAGGCGGAGC AGCAGCAGCT CATCGACGAC CACTTCCTCT TCGACAAGCC CGTGTCGCCC 600 CTGCTGCTGG CCTCGGGCAT GGCCCGCGAC TGGCCCGACG CCGCGCGTAT CTGGCACAAT 660 GACAATAAGA CCTTCCTGGT GTGGGTCAAC GAGGAGGACC ACCTGCGGGT CATCTCCATG 720 CAGAAGGGGG GCAACATGAA GGAGGTGTTC ACCCGCTTCT GCACCGGCCT CACCCAGATT 780 GAAACTCTCT TCAAGTCTAA GGACTATGAG TTCATGTGGA ACCCTCACCT GGGCTACATC 840 CTCACCTGCC CATCCAACCT GGGCACCGGG CTGCGGGCAG GTGTCGATAT CAAGCTGCCC 900 AACCTGGGCA AGCATGAGAA GTTCTCGGAG GTGCTTAAGC GGCTGCGACT TCAGAAGCGA 960 GGCACAGGCG GTGTGGACAC GGCTGCGGTG GGCGGGGTCT TCGACGTCTC CAACGCTGAC 1020 CGCCTGGGCT TCTCAGAGGT GGAGCTGGTG CAGATGGTGG TGGACGGAGT GAAGCTGCTC 1080 ATCGAGATGG AACAGCGGCT GGAGCAGGGC CAGGCCATCG ACGACCTCAT GCCTGCCCAG 1140 AAATGA 1146 (2) INFORMATION FOR SEQ ID NO:2 ' : ' (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1146 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: YES (v) FRAGMENT TYPE: N-terminal (xi) SEQUENCE, DESCRIPTION: SEQ ID NO:2: ATGCCATTCG GTAACACCCA CAACAAGTTC AAGCTGAATT ACAAGCCTGA GGAGGAGTAC 60 CCCGACCTCA GCAAACATAA CAACCACATG GCCAAGGTAC TGACCCTTGA ACTCTACAAG 120 AAGCTGCGGG ACAAGGAGAT CCCATCTGGC TTCACTGTAG ACGATGTCAT CCAGACAGGA 180 GTGGACAACC CAGGTCACCC CTTCATCATG ACCGTGGGCT GCGTGGCTGG TGATGAGGAG 240 TCCTACGAAG TTTTCAAGGA ACTCTTTGAC CCCATCATCT CGGATCGCCA CGGGGGCTAC 300 AAACCCACTG ACAAGCACAA GACTGACCTC AACCATGAAA ACCTCAAGGG TGGAGACGAC 360 CTGGACCCCA ACTACGTGCT CAGCAGCCCG GTCCGCACTG GCCGCAGCAT CAAGGGCTAC 420 ACGTTGCCCC CACACTGCTC CCGTGGCGAG CGCCGGGCGG TGGAGAAGCT CTCTGTGGAA 480 GCTCTCAACA GCCTGACGGG CGAGTTCAAA GGGAAGTACT ACCCTCTGAA GAGCATGACG 540 GAGAAGGAGC AGCAGCAGCT CATCGATGAC CACTTCCAGT TCGACAAGCC CGTGTCCCCG 600 CTGCTGCTGG CCTCAGGCAT GGCCCGCCAC TGGCCCGACG CCCCTGGCAT CTGGCACAAT 660 GACAACAAGA GCTTCCTGGT GTGGGTGAAC GAGGAGGATC ACCTCCGGGT CATCTCCATG 720 GAGAAGGGGG GCAACATGAA GGAGGTTTTC CGCCGCTTCT GCGTAGGGCT GCAGAAGATT 780 GAGGAGATCT TTAAGAAAGC TGGCCACCCC TTCATGTGGA ACCAGCACCT GGGCTACGTG 840 CTCACCTGCC CATCCAACCT GGGCACTGGG CTGCGTGGAG GCGTGCATGT GAAGCTGGCG 900 CACCTGAGCA AGCACCCCAA GTTCGAGGAG ATCCTCACCC GCCTGCGTCT GCAGAAGAGG 960 GGTACAGGTG CGGTGGACAC AGCTGCCGTG GGCTCAGTAT TTGACGTGTC CAACGCTGAT 1020 CGGCTGGGCT CGTCCGAAGT AGAACAGGTG CAGCTGGTGG TGGATGGTGT GAAGCTCATG 1080 GTGGAAATGG AGAAGAAGTT GGAGAAAGGC CAGTCCATCG ACGACATGAT CCCCGCCCAG 1140 AAGTAG 1146 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 381 a ino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear ( ii ) MOLECULE TYPE : protein (v) FRAGMENT TYPE : N-terminal (xi ) SEQUENCE DESCRIPTION : SEQ ID NO : 3 : Met Pro Phe Ser Asn Ser His Asn Ala Leu Lys Leu Arg Phe Pro Ala 1 5 10 15 Glu Asp Glu Phe Pro Asp Leu Ser Ala His Asn Asn His Met Ala Lys 20 25 30 Val Leu Thr Pro Glu Leu Tyr Ala Asp Val Arg Ala Lys Ser Thr Pro 35 40 45 Ser Gly Phe Thr Leu Asp Asp Val lie Gin Thr Gly Val Asp Asn Pro 50 55 60 Gly His Pro Tyr lie Met Thr Val Gly Cys Val Ala Gly Asp Glu Glu 65 70 75 80 Ser Tyr Glu Val Phe Lys Asp Leu Phe Asp Pro lie lie Glu Asp Arg 85 90 95 His Arg Arg Tyr Lys Pro Ser Asp Asp Asp Lys Thr Asp Leu Asn Pro 100 105 110 Asp Asn Leu Gin Gly Gly Asp Asp Leu Asp Pro Asn Tyr Val Leu Ser 115 120 125 Ser Arg Val Ala Thr Gly Arg Ser He Arg Gly Phe Cys Leu Pro Pro 130 135 140 His Cys Ser Arg Gly Glu Arg Arg Ala He Glu Lys Leu Ala Val Glu 145 150 155 160 Ala Leu Ser Ser Leu Asp Gly Asp Leu Ala Gly Arg Tyr Tyr Ala Leu 165 170 175 Lys Ser Met Thr Glu Ala Glu Gin Gin Gin Leu He Asp Asp His Phe 180 185 190 Leu Phe Asp Lys Pro Val Ser Pro Leu Leu Leu Ala Ser Gly Met Ala 195 200 205 Arg Asp Trp Pro Asp Ala Ala Arg He Trp His Asn Asp Asn Lys Thr 210 215 220 Phe Leu Val Trp Val Asn Glu Glu Asp His Leu Arg Val He Ser Met 225 230 235 240 Gin Lys Gly Gly Asn Met Lys Glu Val Phe Thr Arg Phe Cys Thr Gly 245 250 255 Leu Thr Gin He Glu Thr Leu Phe Lys Ser Lys Asp Tyr Glu Phe Met 260 265 270 Trp Asn Pro His Leu Gly Tyr He Leu Thr Cys Pro Ser Asn Leu Gly 275 280 285 Thr Gly Leu Arg Ala Gly Val Asp He Lys Leu Pro Asn Leu Gly Lys 290 295 300 His Glu Lys Phe Ser Glu Val Leu Lys Arg Leu Arg Leu Gin Lys Arg 305 310 315 320 Gly Thr Gly Gly Val Asp Thr Ala Ala Val Gly Gly Val Phe Asp Val 325 330 335 Ser Asn Ala Asp Arg Leu Gly Phe Ser Glu Val Glu Leu Val Gin Met 340 345 350 Val Val Asp Gly Val Lys Leu Leu He Glu Met Glu Gin Arg Leu Glu 355 360 365 Gin Gly Gin Ala He Asp Asp Leu Met Pro Ala Gin Lys 370 375 380 10 15 20 25 30 35 40 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 381 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear ( ii ) MOLECULE TYPE : protein (v) FRAGMENT TYPE : N- terminal (xi ) SEQUENCE DESCRIPTION : SEQ ID NO : 4 : Met Pro Phe Gly Asn Thr His Asn Lys Phe Lys Leu Asn Tyr Lys Pro 1 5 10 15 Glu Glu Glu Tyr Pro Asp Leu Ser Lys His Asn Asn His Met Ala Lys 20 25 30 Val Leu Thr Leu Glu Leu Tyr Lys Lys Leu Arg Asp Lys Glu He Pro 35 40 45 Ser Gly Phe Thr Val Asp Asp Val He Gin Thr Gly Val Asp Asn Pro 50 55 60 Gly His Pro Phe He Met Thr Val Gly Cys Val Ala Gly Asp Glu Glu 65 70 75 80 Ser Tyr Glu Val Phe Lys Glu Leu Phe Asp Pro He He Ser Asp Arg 85 90 95 His Gly Gly Tyr Lys Pro Thr Asp Lys His Lys Thr Asp Leu Asn His 100 105 110 Glu Asn Leu Lys Gly Gly Asp Asp Leu Asp Pro Asn Tyr Val Leu Ser 115 120 125 Ser Pro Val Arg Thr Gly Arg Ser He Lys Gly Tyr Thr Leu Pro Pro 130 135 140 His Cys Ser Arg Gly Glu Arg Arg Ala Val Glu Lys Leu Ser Val Glu 145 150 155 160 Ala Leu Asn Ser Leu Thr Gly Glu Phe Lys Gly Lys Tyr Tyr Pro Leu 165 170 175 Lys Ser Met Thr Glu Lys Glu Gin Gin Gin Leu He Asp Asp His Phe 180 185 190 Gin Phe Asp Lys Pro Val Ser Pro Leu Leu Leu Ala Ser Gly Met Ala 195 200 205 Arg His Trp Pro Asp Ala Pro Gly He Trp His Asn Asp Asn Lys Ser 210 215 220 Phe Leu Val Trp Val Asn Glu Glu Asp His Leu Arg Val He Ser Met 225 230 235 240 Glu Lys Gly Gly Asn Met Lys Glu Val Phe Arg Arg Phe Cys Val Gly 245 250 255 Leu Gin Lys He Glu Glu He Phe Lys Lys Ala Gly His Pro Phe Met 260 265 270 Trp Asn Gin His Leu Gly Tyr Val Leu Thr Cys Pro Ser Asn Leu Gly 275 280 285 Thr Gly Leu Arg Gly Gly Val His Val Lys Leu Ala His Leu Ser Lys 290 295 300 His Pro Lys Phe Glu Glu He Leu Thr Arg Leu Arg Leu Gin Lys Arg 305 310 315 320 Gly Thr Gly Ala Val Asp Thr Ala Ala Val Gly Ser Val Phe Asp Val 325 330 335 Ser Asn Ala Asp Arg Leu Gly Ser Ser Glu Val Glu Gin Val Gin Leu 340 345 350 Val Val Asp Gly Val Lys Leu Met Val Glu Met Glu Lys Lys Leu Glu 355 360 365 Lys Gly Gin Ser He Asp Asp Met " fie Pro Ala Gin Lys 370 375 380

Claims: CLAIMS 1. A method of producing an eukaryotic heterodimeric enzyme in an active form, comprising: (a) constructing: (i) a first DNA vector containing DNA encoding a first subunit of the enzyme; and (ii) a second DNA vector containing DNA encoding a second subunit of the enzyme; (b) transforming a prokaryotic host with: (i) the first DNA vector; and (ii) the second DNA vector; and (c) culturing the transformed prokaryotic host under conditions appropriate for the expression of the dimeric enzyme. 2. The method of Claim 1 wherein the eukaryotic heterodimeric enzyme is mammalian. 3. The method of Claim 1 wherein the eukaryotic heterodimeric enzyme is a kinase. 4. The method of Claim 3 wherein the kinase is a creatine kinase. 5. The method of Claim 1 wherein: (a) the first subunit is creatine kinase subunit B and second subunit is creatine kinase subunit M; or (b) the first subunit is creatine kinase subunit M and second subunit is creatine kinase subunit B. 6. The method of Claim 1 wherein the prokaryotic host is bacterial. 7. The method of Claim 6 wherein the bacterial host is a Escherichia. 8. A method of producing a human dimeric enzyme comprising: (a) constructing: (i) a first DNA vector containing DNA encoding a first subunit of the enzyme; and (ii) second DNA vector containing DNA encoding a second subunit of the enzyme; (b) transforming a prokaryotic host with: (i) the first DNA vector; and (ii) the second DNA vector; and (c) culturing the transformed prokaryotic host under conditions appropriate for the expression of the heterodimeric enzyme. 9. The method of Claim 8 wherein the human dimeric enzyme is a kinase. 10. The method of Claim 9 wherein the kinase is creatine kinase. 11. The method of Claim 8 wherein the prokaryotic host is bacterial. 12. The method of Claim 11 wherein the bacterial host is a Escherichia . 13. The method of Claim 8 wherein the first and second subunit are creatine kinase subunit B. 14. The method of Claim 8 wherein the first and second subunit are creatine kinase subunit M. 15. A method of producing a creatine kinase enzyme comprising: (a) constructing: (i) a first DNA vector containing DNA encoding a DNA sequence selected from all or a portion of the DNA sequence of SEQ ID NO. :1; and (ii) a second DNA vector containing DNA encoding a DNA sequence selected from all or a portion of the DNA sequence of SEQ ID NO.:2; (b) transforming a bacterial host with: (i) the first DNA vector; and (ii) the second DNA vector; and (c) culturing the transformed bacterial host under conditions appropriate for the expression of the dimeric enzyme. 16. A method of producing a creatine kinase enzyme comprising: (a) constructing: (i) a first DNA vector containing DNA encoding a DNA sequence selected from all or a portion of the DNA sequence of SEQ ID NO. :2 ; and (ii) a second DNA vector containing DNA encoding a DNA sequence selected from all or a portion of the DNA sequence of SEQ ID NO.:l; (b) transforming a bacterial host with: (i) the first DNA vector; and (ii) the second DNA vector; and (c) culturing the transformed bacterial host under conditions appropriate for the expression of the dimeric enzyme. 17. An eukaryotic heterodimeric enzyme produced by the method of Claim 1. 18. An human dimeric enzyme produced by the method of Claim 8. 19. A creatine kinase enzyme produced by the method of Claim 15. 20. A creatine kinase enzyme produced by the method of Claim 16. 21. A transformed prokaryotic host produced by the method of Claim 1. 22. A transformed prokaryotic host produced by the method of Claim 8. 23. A transformed prokaryotic host produced by the method of Claim 15. 24. A transformed prokaryotic host produced by the method of Claim 16.

Inventors: LONG SUSAN, ZIEGLER ROBIN J, LONG, SUSAN, ZIEGLER, ROBIN, J.
Applicants: GENZYME CORP, GENZYME CORPORATION
Application year: 1994
Main classification: C12N1
IPC codes: C12N1, C12N9, C12N15, C12R1